Innate Immunity Clinical Trial
Official title:
An Open-Label, Parallel Group, Controlled Study in Healthy Subjects to Characterize Biological Responses to Immunological Challenges and to Measure the Effect of Marketed Anti-Inflammatory Agents on Those Responses
The main objective of this study is to characterize the biological responses elicited by endotoxin inhalation applied to healthy subjects, and to assess the effect of standard anti-inflammatory agents (i.e. adalimumab and methylprednisolone) on these biological responses.
This open-label, single-center, parallel-group clinical trial is designed to evaluate
Humira® or methylprednisolone versus no treatment in healthy subjects applied inhaled
endotoxin challenges.
A total of 30 healthy adult subjects who meet all inclusion and exclusion criteria will be
randomised in a 1:1:1 ratio to one of the following cohorts:
- Cohort 1 subjects receive no study drug during the study.
- Cohort 2 subjects receive an oral 7-day course of the corticosteroid
(methylprednisolone) during the study, starting on study Day 1. The daily dose is 20
mg.
- Cohort 3 subjects receive a single subcutaneous injection of the anti-tumor necrosis
factor (TNF) (adalimumab) on study Day 1, administered as a 40 mg dose.
The study will include a Screening period of up to 21 days, during which subject eligibility
will be assessed and Screening responses to endotoxin exposure challenge will be collected.
Eligible subjects will initially undergo an 8-day treatment period, during which they will
receive treatment based on their assigned cohort (or will receive no treatment if assigned
to Cohort 1) and will be applied with the endotoxin challenges. After the treatment period,
subjects will be followed up until study Day 42.
Efficacy evaluations will include specific responses to endotoxin challenge, and effects of
methylprednisolone and adalimumab on these responses. Safety will be monitored throughout
the study.
;
Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT06123910 -
Bovine Colostrum Supplementation in Athletes
|
N/A | |
Completed |
NCT03639376 -
Passive Smoking and LL-37 in Children
|
||
Recruiting |
NCT04816760 -
Immune Cells Phenotypes During COVID-19
|
||
Completed |
NCT01386489 -
Immune Responses to Two Experimental HIV Vaccines in Healthy Adults
|
Phase 1 | |
Recruiting |
NCT03379207 -
Innate Immune Response During Community Acquired Pneumonia
|
||
Not yet recruiting |
NCT04256356 -
Immunity Modification of Full Term Infants According to the Type of Feeding and Mode of Delivery
|
N/A | |
Completed |
NCT02953327 -
Testing if BCG (Bacille Calmette-Guérin) Vaccination Can Induce Innate Immune Training in Adult People Above 50 Years of Age in Guinea-Bissau
|
Phase 4 | |
Completed |
NCT03637894 -
Immunity Modification of Full Term Infants According to the Type of Feeding and Mode of Delivery
|
N/A | |
Completed |
NCT03886350 -
Implication of UNconventionaL T Lymphocytes in Cystic Fibrosis (UNLOCk)
|